BMY News 49.32 04/30/2014 05:06:26 Bristol-Myers Squibb Company
Post# of 273256
Posted On: 04/30/2014 6:06:13 AM
Bristol-Myers Squibb Company (BMY) 49.32 $BMY
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
Dividend Stock Earnings Roundup: Bristol-Myers Squibb, Merck & Co., and Sanofi
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Earnings season has descended upon us once again, with some of the top names in health care reporting today. So, let's take a closer look at Bristol-Myers Squibb , Merck & Co. , and Sanofi 's first-quarter earnings. Bristol-Myers beats...
Final Glance: Pharmaceuticals companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Oncology Drugs Spur a 51% Jump in Profits For Bristol-Myers Squibb
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:54PM CDT
Global pharmaceutical giant Bristol-Myers Squibb took the "slow but steady wins the race" approach with its first-quarter earnings release before the opening bell this morning. For the quarter, Bristol-Myers' revenue actually fell 1% to $3.81...
Midday Glance: Pharmaceuticals companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why Bristol-Myers Squibb (BMY) Stock Is Down Today
at The Street - Tue Apr 29, 11:44AM CDT
Bristol-Myers Squibb (BMY) fell Tuesday after the pharmaceutical company reported mixed first-quarter earnings and announced it would seek FDA approval of its highly-anticipated drug nivolumab by the end of the year.
Bristol, Merck, Sanofi Report Soft Q1 Sales
at Investor's Business Daily - Tue Apr 29, 11:15AM CDT
Three big pharmas reported light-to-mixed Q1 earnings Tuesday, but their shares went in different directions in the stock market today as Wall Street seemed to focus on different details of the reports. Bristol-Myers Squibb (BMY) said Q1 earnings...
Bristol-Myers profit up 54 pct. on cost cuts, sale
By The Associated Press - AP - Tue Apr 29, 10:56AM CDT
NEW YORK (AP) — Drugmaker Bristol-Myers Squibb Co. reported a 54 percent jump in first-quarter profit, as cost cutting and a gain from selling most of its diabetes business outweighed a slight dip in sales.
Bristol-Myers Beats Earnings in Q1, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:52AM CDT
Bristol-Myers (BMY) first quarter 2014 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Today’s Top Health Care Stories: Novavax, Merck, and Bristol-Myers Squibb
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 29, 8:18AM CDT
Let's take a quick look at three stocks which could loom large in health care headlines this Tuesday morning -- Novavax , Merck , and Bristol-Myers Squibb . Novavax shows positive top-line data for its RSV-F vaccine candidate Novavax...
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Will Bristol-Myers (BMY) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:45PM CDT
Bristol-Myers (BMY) is scheduled to release its first quarter 2014 results before the opening bell on Tuesday, Apr 29.
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
Dividend Stock Earnings Roundup: Bristol-Myers Squibb, Merck & Co., and Sanofi
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Earnings season has descended upon us once again, with some of the top names in health care reporting today. So, let's take a closer look at Bristol-Myers Squibb , Merck & Co. , and Sanofi 's first-quarter earnings. Bristol-Myers beats...
Final Glance: Pharmaceuticals companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Oncology Drugs Spur a 51% Jump in Profits For Bristol-Myers Squibb
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:54PM CDT
Global pharmaceutical giant Bristol-Myers Squibb took the "slow but steady wins the race" approach with its first-quarter earnings release before the opening bell this morning. For the quarter, Bristol-Myers' revenue actually fell 1% to $3.81...
Midday Glance: Pharmaceuticals companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why Bristol-Myers Squibb (BMY) Stock Is Down Today
at The Street - Tue Apr 29, 11:44AM CDT
Bristol-Myers Squibb (BMY) fell Tuesday after the pharmaceutical company reported mixed first-quarter earnings and announced it would seek FDA approval of its highly-anticipated drug nivolumab by the end of the year.
Bristol, Merck, Sanofi Report Soft Q1 Sales
at Investor's Business Daily - Tue Apr 29, 11:15AM CDT
Three big pharmas reported light-to-mixed Q1 earnings Tuesday, but their shares went in different directions in the stock market today as Wall Street seemed to focus on different details of the reports. Bristol-Myers Squibb (BMY) said Q1 earnings...
Bristol-Myers profit up 54 pct. on cost cuts, sale
By The Associated Press - AP - Tue Apr 29, 10:56AM CDT
NEW YORK (AP) — Drugmaker Bristol-Myers Squibb Co. reported a 54 percent jump in first-quarter profit, as cost cutting and a gain from selling most of its diabetes business outweighed a slight dip in sales.
Bristol-Myers Beats Earnings in Q1, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:52AM CDT
Bristol-Myers (BMY) first quarter 2014 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Today’s Top Health Care Stories: Novavax, Merck, and Bristol-Myers Squibb
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 29, 8:18AM CDT
Let's take a quick look at three stocks which could loom large in health care headlines this Tuesday morning -- Novavax , Merck , and Bristol-Myers Squibb . Novavax shows positive top-line data for its RSV-F vaccine candidate Novavax...
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
What You Need to Know About New Hepatitis C Drugs
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
According to Express Scripts 2013 Drug Spending Trends report, spending on hepatitis C drugs will soar 102% this year and more than 200% next year, as doctors increasingly prescribe next-generation treatments from Gilead and Johnson & Johnson...
Will Bristol-Myers (BMY) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 3:45PM CDT
Bristol-Myers (BMY) is scheduled to release its first quarter 2014 results before the opening bell on Tuesday, Apr 29.
Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump
at Investor's Business Daily - Mon Apr 28, 10:39AM CDT
Pfizer (PFE) says it is trying to acquire fellow big pharma AstraZeneca, confirming an anonymously sourced report from last week. Pfizer stock was up 4.5% and AstraZeneca 15% in morning trading on the stock market today. Pfizer bid for AstraZeneca on...
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard
PR Newswire - Mon Apr 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Actavis Plc (NYSE: ACT) and C.R. Bard Inc. (NYSE: BCR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1687-100free.
(0)
(0)Scroll down for more posts ▼